Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pulmatrix (PULM) Research & Development (2016 - 2025)

Pulmatrix (PULM) has disclosed Research & Development for 13 consecutive years, with -$3000.0 as the latest value for Q4 2025.

  • Quarterly Research & Development fell 150.0% to -$3000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $38000.0 through Dec 2025, down 99.47% year-over-year, with the annual reading at $38000.0 for FY2025, 99.47% down from the prior year.
  • Research & Development hit -$3000.0 in Q4 2025 for Pulmatrix, down from $8000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.3 million in Q3 2022 to a low of -$3000.0 in Q4 2025.
  • Historically, Research & Development has averaged $2.8 million across 5 years, with a median of $3.7 million in 2021.
  • Biggest five-year swings in Research & Development: surged 50.96% in 2022 and later plummeted 150.0% in 2025.
  • Year by year, Research & Development stood at $3.0 million in 2021, then soared by 50.96% to $4.5 million in 2022, then decreased by 21.29% to $3.5 million in 2023, then plummeted by 99.83% to $6000.0 in 2024, then tumbled by 150.0% to -$3000.0 in 2025.
  • Business Quant data shows Research & Development for PULM at -$3000.0 in Q4 2025, $8000.0 in Q3 2025, and $14000.0 in Q2 2025.